Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease
Endometrial cancer is one of the most prevalent malignancies in women and the prognosis of metastatic and recurrent disease is dismal, with limited treatment options. Molecular classification based on data from the Cancer Genome Atlas (TCGA) project has markedly improved our understanding of the bio...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.18.126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127977985081344 |
|---|---|
| author | Marta Nerone Maria Del Grande Ilaria Colombo |
| author_facet | Marta Nerone Maria Del Grande Ilaria Colombo |
| author_sort | Marta Nerone |
| collection | DOAJ |
| description | Endometrial cancer is one of the most prevalent malignancies in women and the prognosis of metastatic and recurrent disease is dismal, with limited treatment options. Molecular classification based on data from the Cancer Genome Atlas (TCGA) project has markedly improved our understanding of the biology of endometrial cancer and accelerated the development of immunotherapy for different disease subtypes. The introduction of immune checkpoint inhibitors (ICIs) has led to major progress in the management of advanced endometrial cancer, especially in biomarker-select populations. Multiple clinical trials have assessed the efficacy and safety of immunotherapy alone or in combination with targeted therapy or chemotherapy in advanced and recurrent endometrial cancer. In this review, we summarize data from recent clinical studies on immunotherapeutic alternatives for advanced and refractory endometrial cancer, with a focus on ICI-based regimens.
PEER REVIEWED ARTICLE
Peer reviewers:
Dr Dagmar Hess (Cantonal Hospital St. Gallen St. Gallen, Switzerland);
One anonymous peer reviewer.
Submitted: August 31, 2023 CEST; Accepted: December 06, 2023 CEST |
| format | Article |
| id | doaj-art-61b424b3562644d0b8a7abef6eaba957 |
| institution | OA Journals |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-61b424b3562644d0b8a7abef6eaba9572025-08-20T02:33:31ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062023-12-0118410.36000/HBT.OH.2023.18.126Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent DiseaseMarta NeroneMaria Del GrandeIlaria ColomboEndometrial cancer is one of the most prevalent malignancies in women and the prognosis of metastatic and recurrent disease is dismal, with limited treatment options. Molecular classification based on data from the Cancer Genome Atlas (TCGA) project has markedly improved our understanding of the biology of endometrial cancer and accelerated the development of immunotherapy for different disease subtypes. The introduction of immune checkpoint inhibitors (ICIs) has led to major progress in the management of advanced endometrial cancer, especially in biomarker-select populations. Multiple clinical trials have assessed the efficacy and safety of immunotherapy alone or in combination with targeted therapy or chemotherapy in advanced and recurrent endometrial cancer. In this review, we summarize data from recent clinical studies on immunotherapeutic alternatives for advanced and refractory endometrial cancer, with a focus on ICI-based regimens. PEER REVIEWED ARTICLE Peer reviewers: Dr Dagmar Hess (Cantonal Hospital St. Gallen St. Gallen, Switzerland); One anonymous peer reviewer. Submitted: August 31, 2023 CEST; Accepted: December 06, 2023 CESThttps://doi.org/10.36000/HBT.OH.2023.18.126 |
| spellingShingle | Marta Nerone Maria Del Grande Ilaria Colombo Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease healthbook TIMES. Oncology Hematology |
| title | Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease |
| title_full | Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease |
| title_fullStr | Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease |
| title_full_unstemmed | Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease |
| title_short | Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease |
| title_sort | immune checkpoint inhibitors in endometrial cancer the new paradigm of treatment for advanced and recurrent disease |
| url | https://doi.org/10.36000/HBT.OH.2023.18.126 |
| work_keys_str_mv | AT martanerone immunecheckpointinhibitorsinendometrialcancerthenewparadigmoftreatmentforadvancedandrecurrentdisease AT mariadelgrande immunecheckpointinhibitorsinendometrialcancerthenewparadigmoftreatmentforadvancedandrecurrentdisease AT ilariacolombo immunecheckpointinhibitorsinendometrialcancerthenewparadigmoftreatmentforadvancedandrecurrentdisease |